Q3 Earnings Estimate for Replimune Group Issued By Wedbush

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at Wedbush upped their Q3 2025 earnings per share estimates for Replimune Group in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior forecast of ($0.80). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at ($1.38) EPS.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07.

A number of other research firms have also recently commented on REPL. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Performance

NASDAQ:REPL opened at $11.40 on Friday. The company has a quick ratio of 13.46, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a twelve month low of $4.92 and a twelve month high of $12.97. The stock’s 50 day moving average price is $11.44 and its two-hundred day moving average price is $9.50.

Institutional Trading of Replimune Group

A number of hedge funds have recently made changes to their positions in REPL. Baker BROS. Advisors LP boosted its holdings in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Millennium Management LLC grew its stake in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Braidwell LP grew its stake in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after buying an additional 2,057,460 shares during the period. Finally, Vanguard Group Inc. raised its stake in Replimune Group by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after buying an additional 32,555 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.